| 產(chǎn)品編號(hào) | bs-4790R |
| 英文名稱 | CD8 Rabbit pAb |
| 中文名稱 | CD8抗體 |
| 別 名 | CD8 antigen, alpha polypeptide(p32); CD8a; CD8a antigen; CD8a molecule; CD8A_HUMAN; Leu2; Leu2 T lymphocyte antigen; MAL; OKT8 T cell antigen; p32; T cell antigen Leu2; T cell co receptor; T-cell surface glycoprotein CD8 alpha chain; T-lymphocyte differentiation antigen T8/Leu-2; T8 T cell antigen. |
 |
Specific References (5) | bs-4790R has been referenced in 5 publications.
[IF=16.988] Wu Yutong. et al. Osteoclast-Derived Apoptotic Bodies Inhibit Naive Cd8
T Cell Activation via Siglec15 Promoting Breast Cancer Secondary Metastasis. Cell Reports Medicine. 2022 Nov 03 IHC ; Mouse.
[IF=4.8] Zou, Ming-Xiang, et al. "Clinicopathologic implications of CD8+/Foxp3+ ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients." Cancer Immunology, Immunotherapy (2017): 1-16. IHC-P ; Human.
[IF=4.475] Zou MX et al. Clinical Impact of the Immune Microenvironment in Spinal Chordoma: Immunoscore as an Independent Favorable Prognostic Factor.Neurosurgery. 2018 Jul 19. IHC-P ; Human.
[IF=3.776] Jia-qi Yuan. et al. S100A9 promotes glycolytic activity in HER2-positive breast cancer to induce immunosuppression in the tumour microenvironment. HELIYON. 2023 Feb;9:e13294 IHC ; Human.
[IF=3.427] Gao et al. Common expression of stemness molecular markers and early cardiac transcription factors in human Wharton's jelly-derived mesenchymal stem cells and embryonic stem cells. (2013) Cell.Transplan. 22:1883-900 FCM ; Human.
|
| 研究領(lǐng)域 | 細(xì)胞生物 干細(xì)胞 細(xì)胞表面分子 淋巴細(xì)胞 t-淋巴細(xì)胞 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 克 隆 號(hào) | |
| 交叉反應(yīng) | Mouse,Rat |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 27 kDa |
| 檢測(cè)分子量 | |
| 細(xì)胞定位 | 細(xì)胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CD8: 51-150/235 <Extracellular> |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
The CD8 antigen is a cell surface glycoprotein found on most cytotoxic T lymphocytes that mediates efficient cell-cell interactions within the immune system. The CD8 antigen acts as a coreceptor with the T-cell receptor on the T lymphocyte to recognize antigens displayed by an antigen presenting cell in the context of class I MHC molecules. The coreceptor functions as either a homodimer composed of two alpha chains or as a heterodimer composed of one alpha and one beta chain. Both alpha and beta chains share significant homology to immunoglobulin variable light chains. This gene encodes the CD8 alpha chain. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2011]. Function: Identifies cytotoxic/suppressor T-cells that interact with MHC class I bearing targets. CD8 is thought to play a role in the process of T-cell mediated killing. CD8 alpha chains binds to class I MHC molecules alpha-3 domains. Subunit: In general heterodimer of an alpha and a beta chain linked by two disulfide bonds. Can also form homodimers. Shown to be expressed as heterodimer on thymocytes and as homodimer on peripheral blood T-lymphocytes. Interacts with the MHC class I HLA-A/B2M dimer. Interacts with LCK in a zinc-dependent manner. Subcellular Location: Membrane; Single-pass type I membrane protein. Similarity: Contains 1 Ig-like V-type (immunoglobulin-like) domain. SWISS: P01732 Gene ID: 925 Database links: Entrez Gene: 925 Human Omim: 186910 Human SwissProt: P01732 Human Unigene: 85258 Human |
| 產(chǎn)品圖片 |
25 ug total protein per lane of various lysates (see on figure) probed with CD8 polyclonal antibody, unconjugated (bs-4790R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.
|
